Previous 10 | Next 10 |
SOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the start of additional marketing initiatives focusing on the launch of a patient and physi...
SOLANA BEACH, Calif., CHICAGO, and MOUNT PLEASANT, S.C., June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, EVERSANA™, a leading provider of global commercial services to th...
Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.The study aimed to gather further market insights on perception of GIMOTI in the GI community. In May 2021, Evoke’s commercialization partner, EVER...
SOLANA BEACH, Calif. and CHICAGO, June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science indu...
Evoke Pharma (EVOK) jumps 8.4% premarket in reaction to the announcement that its US patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the FDA's “Orange Book”.The patent covers methods of use for nasal delivery of metoclopramide for th...
SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti ® (metoclopramide) nasal spray is now...
Evoke Pharma (EVOK) announces that the United States Patent and Trademark Office ((USPTO)) has issued US patent no. 11,020,361 to the company related to Gimoti (metoclopramide) nasal spray. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of ga...
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments...
Evoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a ...
The stock price has been decimated after a sluggish commercial launch for Gimoti. COVID is not likely the only problem. The January funding will not be enough - Evoke will need to raise $20 mil to $60 mil to get to cash flow positive. The best outcome for current investors is prob...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK)...